• Prime Medicine secured FDA clearance for an IND for PM647, an in vivo prime editor for alpha-1 antitrypsin deficiency.
• Clearance enables a Phase 1/2 global, single-arm, open-label study of a one-time IV infusion in adults.
• Initial enrollment targets lung-only patients; a separate cohort with significant liver disease is planned following tolerability.
• Initial clinical data are expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241601PRIMZONEFULLFEED9833685) on September 24, 2026, and is solely responsible for the information contained therein.